Which patients with prostate cancer are actually candidates for hormone therapy?

International Braz J Urol

Volumn 30, Issue 6, 2004, Pages 455-465

  Sciarra, Alessandro ^a,b   Cardi, Antonio ^a   Salvatori, Gianfilippo ^a   D'Eramo, Giuseppe ^a   Mariotti, Gianna ^a   Di Silverio, Franco ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Carcinoma; Hormone therapy; Prostatic neoplasms

Indexed keywords

ANDROGEN; ANGIOPEPTIN; ANTIANDROGEN; BICALUTAMIDE; ESTROGEN; ETHINYLESTRADIOL; GOSERELIN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SOMATOSTATIN DERIVATIVE;

ADVANCED CANCER; AGE; ANTIGEN DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; DRUG TOLERABILITY; EARLY CANCER; HUMAN; PATIENT CODING; PATIENT SELECTION; PROSTATE CANCER; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; SOCIETY; TREATMENT INDICATION; UROLOGIC SURGERY;

EID: 12744260424     PISSN: 16775538     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1677-55382004000600002     Document Type: Article

References (41)

1. Parker SL, Tong T, Bolden S, Wingo PA: Cancer Statistic 1997. CA Cancer J Clin. 1997; 47: 5-27. Erratum in: CA Cancer J Clin. 1997; 47: 68.
2. Carter HB, Coffey DS: The prostate: an increasing medical problem. Prostate. 1990; 16: 39-48.
3. Kirby RS, Christmas TJ, Brawer MK: Prostate Cancer, 2nd International Consultation on Prostate Cancer. Paris, Mosby. 1999; pp. 21-56.
4. Byar DP: Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973; 32: 1126-30.
5. The Medical Research Council Prostate Cancer Working Party Investigator Group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Br J Urol. 1997; 79: 235-46.
6. Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D, et al.: Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center. Eur Urol. 1998; 33: 144-51.
7. Kirby RS, Christmas TJ, Brawer MK: Prostate Cancer, 2nd International Consultation on Prostate Cancer. Paris, Mosby. 1999, pp. 327-350.
8. Wilt TJ, Brawer MK: The prostate cancer intervention versus observation trial (PIVOT). Cancer. 1994; 75: 1963-68.
9. Barre M, Nerstrom B, Overgaard J: The natural history of prostate carcinoma based on a Danish population treated with no attempt to cure. Cancer. 1997; 80: 917-28.
10. Monti S, Sciarra A, Falasco P: Serum concentrations and prostatic gene expression of Chromogranin A and PSA in patients affected by prostate cancer and benign prostatic hyperplasia. J Endocrin Invest. 2000; 23 (Suppl. 8): 53A.
11. Sciarra A, Mariotti G, Gentile V, Pastore A, Voria G, Di Silverio F, et al.: Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU Int. 2003; 91: 438-45.
12. Sciarra A, Monti S, Gentile V, Mariotti G, Cardi A, Voria G, et al.: Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Prostate. 2003; 55: 168-79.
13. Sciarra A, Gentile V, Pastore A, Voria G, Mariotti G, Di Silverio F, et al.: Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Eur Urol. 2003; 49 (Suppl. 2): 742A.
14. Schroder FH: Antiandrogen as monotherapy for prostate cancer. Eur Urol. 1998; 34 (Suppl. 3): 12-7.
15. Debruyne FMJ, Akaza H, Klotz L: Innovative Approaches in Medical Management of Prostate Cancer: Hormones, 5th International Consultation on Prostate Cancer. Paris, J.R. Spermon. 2003.
16. Kirby RS, Christmas TJ, Brawer MK: Prostate Cancer, 2nd International Consultation Prostate Cancer. Paris, Mosby. 1999; pp. 263-326.
17. Lu Yao GL, Yao SL: Population-based study of long term survival in patients with clinically localized prostate cancer. Lancet. 1997; 349: 906-10.
18. Roach M: Neoadiuvant therapy prior to radiotherapy for clinically localized prostate cancer. Eur Urol. 1997; 32 (Suppl. 3): 48-54.
19. Gleave ME: Randomized, comparative study of 3 vs 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy. Biochemical and pathological effects. J Urol. 1999; 161 (Suppl.): 592A.
20. Lerner SE, Blute ML, Zincke H: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcomes and contemporary morbidity. J Urol. 1995; 154: 1447-52.
21. Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al.: Improve survival in patient with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997; 337: 295-300.
22. Gomez JL, Cusan L, Diamond P, Candas B, Labrie F: Long term treatment of clinical stage C/T3 prostate cancer with flutamide and castration: 6 year median follow-up. Br J Urol. 1997; 80 (Suppl. 2): 275.
23. Rana A, Crisholm GD, Khan M, Rashwan HM, Elton RA: Conservative management with symptomatic treatment and delayed hormonal manipulation is justified in men with locally advanced carcinoma of the prostate. Br J Urol. 1994; 74: 637-41.
24. van den Ouden D, Davidson PJ, Hop W, Schroder FH: Radical prostatectomy as a monotherapy for locally advanced (stage T3) prostate cancer. J Urol. 1994; 151: 646-51.
25. Zincke H, Utz DC, Taylor WF: Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: role of adjuvant treatment for residual cancer and disease progression. J Urol. 1986; 135: 1199-205.
26. Seay TM, Blute ML, Zincke H: Long term outcome in patient with pTx N+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol. 1998; 159: 357-64.
27. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H: Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTx N+ prostate cancer: a matched comparison. J Urol. 1999; 162: 1223-7.
28. Messing E, Manola J, Wilding G, Sarosdy M; Crawford D; Trump D: Immediate hormonal therapy vs observation for node positive prostate cancer following radical prostatectomy and pelvic limphadenectomy: a randomized phase III Eastern Cooperative Oncology Group/Inter Group Trial. J Urol. 1999; 161 (Suppl.): 175.
29. Schroder FH: Endocrine treatment of prostate cancer - recent developments and the future. Part 1: maximal androgen blockade, early vs delayed endocrine treatment and side-effects. BJU Int. 1999; 83: 161-70.
30. Kirby RS, Christmas TJ, Brawer MK: Prostate Cancer, 2nd International Consultation on Prostate Cancer. Paris, Mosby. 1999; pp. 351-395.
31. Tyrrell CJ, Kaisary AV, Iversen P, Anderson JB, Baert L, Tammela T, et al.: A randoinised comparison of 'Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol. 1998; 33: 447-56.
32. See WA, McLeod DG, Wirth MP, Iversen P, Klimberg I, Gleason D, et al.: Bicalutamide ("Casodex") 150mg as immediate or adjuvant therapy in 8113 men with localized or locally advanced CaP. J Urol. 2001; 165 (Suppl. 5): 1594A.
33. Swedish Breast Cancer Cooperative Group: Randomized trial of two versus five years of adjuvant tamoxifene for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996; 88: 1543-9.
34. Parkin DM, Pisani P, Ferlay J: Global cancer statistics. CA Cancer J Clin. 1999; 49: 33-64.
35. Varricchio CG, McCabe MS, Trimble E, Korn EL: Quality of Life in Clinical Cancer Trials. Introduction. J Natl Cancer Inst Monogr. 1996; 20: vii-viii.
36. Kirk D, On behalf of the Medical Reserch Council Prostate Working Party Investigator Group Medical Research Council: Immediate versus deferred treatment study: how important is local progression in advanced prostate cancer? Br J Urol. 1998; 81 (Suppl. 4): 30A.
37. Oliver RTD, Williams G, Paris AMI: Intermittent androgen deprivation after PSA-complete response as a strategy to reduce induction of hormone-resistant prostate cancer. Urology. 1997; 49: 79-82
38. Sciarra A, Di Chiro C, Di Silverio F: Intermittent androgen deprivation (IAD) in patients with biochemical failure after radical retropubic prostatectomy (RRP) for clinically localized prostate cancer. World J Urol. 2000; 18: 392-400.
39. Grossfeld GD, Small EJ, Carrell PR: Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. 1998; 51: 137-44.
40. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T: A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab. 2001; 86: 5729-36.
41. Sciarra A, Gentile V, Voria G, Pastore A, Mariotti G, Di Silverio F, et al.: A combination therapy with ethinylestradiol and lanreotide reintroduce responsiveness in androgen ablation therapy in refractory prostate cancer. Eur Urol. 2003; 1: (Suppl 2), 739A.